2Department of Radiology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
3Department of Internal Medicine, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
4Department of Radiology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
Abstract
Objective: To assess the effects of percutaneous transluminal angioplasty and stenting (PTRA/S) on arterial blood pressure and renal function. Methods: A retrospective chart review of patients undergoing PTRA/S at our institution between December 2003 and September 2006 was done. Follow-up data were derived from hospital records. Estimated glomerular filtration rate (EGFR) was used as the marker of renal function. To evaluate the pre- and post-procedure values in individual patients the paired t test and Wilcoxon signed-rank tests were used. Results: Thirty-six patients (16 women, 30 men; mean age 59±15 years, range: 25-83 years) underwent 43 PTRA/S interventions at our institution. The mean duration of follow-up was 9.3±8.6 (range 2-28) months. We observed no significant change in EGFR from pre-procedure to that obtained at follow-up (71.4±40.2 mL/min vs.73.3±39.0 mL/min; p=0.483). Mean arterial blood pressure (MABP), however, was reduced significantly: pre-procedure MABP-123±22 mmHg; post-procedure follow-up value of 101±14 mmHg (p <0.001). The mean number of antihypertensive medications used at the time of intervention was 2.1±1.0 (range: 0-4), whereas at follow-up, this number had decreased to 1.3±1.0 (range: 0-4; p<0.001). In patients with renal impairment (EGFR ≤59 mL/min), 41% showed improvement, 29% showed no change and 29% demonstrated deterioration in EGFR. Conclusion: PTRA/S may preserve renal function, especially in patients with pre-procedural impaired renal function.